Mar. 19 at 9:28 PM
$AUTL when is sp gonna reflect progress? Am Not greedy, just give me
$8-20,
i will be happy to move on…
Key Points
Autolus reported
$75 million in first-year revenue from the launch of obe-cel, reached market leadership by Q2, and is guiding
$120M–
$135M in net revenue for the current year while expanding U.S. delivery from ~70 to 80+ centers and targeting positive gross margin in year two.
The company achieved a manufacturing success rate substantially above 90% with no current capacity limits, and is prioritizing throughput, supply‑chain improvements and automation to boost gross margins over the next 24–36 months.
Real-world ROCCA data showed strong safety and efficacy—zero high‑grade CRS, 3% high‑grade ICANS, zero treatment‑related mortality and an overall response rate >90%—and Autolus is advancing pivotal programs in pediatric ALL and lupus nephritis while exploring progressive MS and other indications.
https://www.marketbeat.com/instant-alerts/autolus-therapeutics-touts-75m-year-1-obe-cel-launch-sees-120m-135m-revenue-in-2026-2026-03-05/?utm_source=yahoofinance&utm_medium=yahoofinance
